drugset / Trial / NCT00529529
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily \[od\]), compared with salmeterol (50 μg twice a day \[b.i.d.\]), over 26 weeks, in patients with moderate to severe persistent asthma.
Timeline
- Start
- 2007-09
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Indacaterol | Other / unclassified | 300 ug | Inhaled |
| Subject | Indacaterol | Other / unclassified | 600 ug | Inhaled |
| Subject | Salmeterol | Other / unclassified | 50 ug | Inhaled |